Another important point that could be highlighted is that AsiDNA, in contrast with other anticancer treatments, is not an inhibitor of a specific target involved in tumour growth, but it is a decoy agonist (AsiDNA binds and activates in particular DNA-PK and redirects it away from sites of tumour DNA damage). This evidence concerns the gene PRKDC and neoplasm.